Lineage Cell Therapeutics

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalmic conditions, today announced that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (.» Mehr auf businesswire.com

Squarepoint Ops LLC acquired a new stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 92,001 shares of the company’s stock, valued at approximately $46,000. Several other institutional investors have also bought and sold shares of the company. Raffles Associates LP lifted its stake in Lineage Cell Therapeutics by 21.8% in the fourth quarter. Raffles Associates LP now owns 5,492,088 shares of the company’s stock valued at $2,760,000 after purchasing an additional 984,307 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in Lineage Cell Therapeutics in the fourth quarter valued at approximately $1,984,000. DAFNA Capital Management LLC lifted its stake in Lineage Cell Therapeutics by 85.9% in the fourth quarter. DAFNA Capital Management LLC now owns 2,511,374 shares of the company’s stock valued at $1,262,000 after purchasing an additional 1,160,666 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Lineage Cell Therapeutics by 1,058.3% in the fourth quarter. Renaissance Technologies LLC now owns 2,283,072 shares of the company’s stock valued at $1,147,000 after purchasing an additional 2,085,972 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new position in Lineage Cell Therapeutics in the fourth quarter valued at approximately $519,000. Hedge funds and other institutional investors own 62.47% of the company’s stock. Analyst Upgrades and Downgrades Several equities analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Lineage Cell Therapeutics in a research note on Tuesday, March 11th. D. Boral Capital reiterated a “buy” rating and issued a $2.00 price objective on shares of Lineage Cell Therapeutics in a research note on Tuesday, March 11th. Finally, B. Riley dropped their price objective on Lineage Cell Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, March 14th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $4.20. View Our Latest Stock Report on LCTX Lineage Cell Therapeutics Price Performance NYSEAMERICAN:LCTX opened at $0.75 on Wednesday. The company has a market cap of $164.23 million, a P/E ratio of -6.21 and a beta of 1.21. The stock’s fifty day moving average price is $0.51 and its two-hundred day moving average price is $0.62. Lineage Cell Therapeutics, Inc. has a 1 year low of $0.37 and a 1 year high of $1.15. About Lineage Cell Therapeutics (Free Report) Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. See Also Five stocks we like better than Lineage Cell Therapeutics Overbought Stocks Explained: Should You Trade Them? AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway Should You Invest in Penny Stocks? Casey’s Surges on Strong Q4, More Gains Likely Ahead Options Trading – Understanding Strike Price Government Mandate Sends eVTOL Stocks Flying» Mehr auf defenseworld.net

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalmic conditions, today announced additional presenters to the 3rd Annual Spinal Cord Injury Investor Symposium ("3rd SCIIS"). The 3rd SCIIS will be a fully virtual event, with interactive and on-demand sessions available starting on June 27, 2025. “We are excite.» Mehr auf businesswire.com